Insulet Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Insulet Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Debt due within a year is covered 30.9 times by its yearly operating cash. Higher than 92% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 3 of the last 3 years; profit grew in 2 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$131Over the last 3 years, every $100 of reported profit came with $131 of operating cash.
Lower than 63% of Healthcare companies in United States.
Self-Funding Ratio
2.5×Over the last 3 years its own operating cash covered its investment spending (capex) 2.5 times.
Higher than 77% of Healthcare companies in United States.
Cash Locked Ratio
$33For every $100 of sales, $33 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $40 tied up three years earlier.
More money tied up than 71% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
3/3 · 2/3Sales grew in 3 of the last 3 years; profit grew in 2 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$17Sales grew 107% in 3 years; of every extra $100 of sales, $17 became extra profit.
Lower than 52% of Healthcare companies in United States.
Asset Productivity Ratio
+107% / +42%In 3 years sales changed by +107% while total assets changed by +42%. Sales grew faster than assets.
Balance-sheet strength
Debt Due Cover Ratio
30.9×Debt due within a year is covered 30.9 times by its yearly operating cash.
Higher than 92% of Healthcare companies in United States.
Cash Cushion Ratio
−2%Debt, after subtracting cash, equals 2% of its market value (net debt).
Lower than 71% of Healthcare companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 71% of Healthcare companies in United States.
Tangible Net Worth Ratio
89%Of every $100 of net worth, $89 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 71% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Insulet Corporation owes $0.55 for every $1 it owns. Net profit fell 41% in the year to Dec 2025, and grew 277% a year on average over 3 years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
27.9Investors pay $27.9 for every $1 of Insulet Corporation's yearly profit, higher than 54% of Healthcare companies in United States.
P/B ratio
7.27The share price is 7.27 times Insulet Corporation's book value per share, higher than 81% of Healthcare companies in United States.
Market cap
$10.3 BThe total market value of all of Insulet Corporation's shares at today's price (share price × number of shares), larger than 90% of Healthcare companies in United States. PosiCap size class: Meso Cap.
Net worth (book value)
$1.4 BWhat Insulet Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$20.51Net worth divided by the number of shares. The share price of $149.01 is 7.3 times this, which is the P/B above.
Return on equity (ROE)
26.0%Insulet Corporation earned 26.0% on its shareholders' money over the last year, higher than 93% of Healthcare companies in United States.
Owes vs Owns
0.55×Insulet Corporation owes $0.55 for every $1 it owns (moderate), higher than 60% of Healthcare companies in United States.
Dividend yield
NoneInsulet Corporation does not currently pay a dividend.
Revenue growth
+31%Revenue rose 31% in the year to Dec 2025, and grew 28% a year on average over 3 years.
Profit growth
-41%Net profit fell 41% in the year to Dec 2025, and grew 277% a year on average over 3 years.
Profit margin
9.1%Insulet Corporation keeps $9 of every $100 of revenue as net profit.
Cash quality
2.3×Cash from Insulet Corporation's business was 2.3× its reported profit in the year to Dec 2025 — its profit turned into cash.
Interest cover
8.0×Insulet Corporation's operating profit covered its interest costs 8.0 times in the year to Dec 2025.
Cash vs debt
Net debtInsulet Corporation had $233 M more debt than cash (net debt) at Dec 2025.
Questions
What is Insulet Corporation's P/E ratio?
Investors pay $27.9 for every $1 of Insulet Corporation's yearly profit, higher than 54% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Insulet Corporation: $10.3 B ÷ $1.4 B (30 Jun 2026) = 7.3.
What is Insulet Corporation's return on equity?
Insulet Corporation earned 26.0% on its shareholders' money over the last year, higher than 93% of Healthcare companies in United States.
How much does Insulet Corporation owe compared with what it owns?
Insulet Corporation owes $0.55 for every $1 it owns (moderate), higher than 60% of Healthcare companies in United States.
Does Insulet Corporation pay a dividend?
No. Insulet Corporation does not currently pay a dividend.
Is Insulet Corporation's revenue growing?
Revenue rose 31% in the year to Dec 2025, and grew 28% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.